I have a question perhaps for some of our more learned contributors on HC.
if for whatever reason PYC's retinitis therapy doesnt achieve any kind of efficacy (perhaps the drug cant be delivered to the cells efficiently?) does that downgrade the likelihood of efficacy in PYC's other pipeline therapies? or are are all the therapies mutually exclusive in that regard because they are each targeting differnet kinds of cells?
thanks in advance.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.005(0.42%) |
Mkt cap ! $691.1M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.21 | $1.19 | $410.5K | 343.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15611 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |